Patents by Inventor Gregory Matlashewski

Gregory Matlashewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LIVE ATTENUATED LEISHMANIA PARASITE VACCINES WITH ENHANCED SAFETY CHARACTERISTICS
    Publication number: 20230039456
    Abstract: Disclosed herein are modified Leishmania species and compositions thereof, such as live, attenuated organisms, immunogenic compositions, vaccines, and pharmaceutical compositions. Further disclosed are methods related to the modified Leishmania species, such as methods of production and methods of use.
    Type: Application
    Filed: December 17, 2020
    Publication date: February 9, 2023
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, Ohio State Innovation Foundation
    Inventors: Hira L. Nakhasi, Ranadhir Dey, Sreenivas Gannavaram, Subir Karmakar, Gregory Matlashewski, Abhay Satoskar, Wen-Wei Zhang, Patrick Lypaczewski
  • Attenuated strain of Leishmania
    Patent number: 6133017
    Abstract: Differentially expressed Leishmania genes and proteins are described. One differentially expressed gene (A2) is expressed at significantly elevated levels (more than about 10 fold higher) in the amastigote stage of the life cycle when the Leishmania organism is present in macrophages than in the free promastigote stage. The A2 gene encodes a 22 kD protein (A2 protein) that is recognized by kala-azar convalescent serum and has amino acid sequence homology with an S-antigen of Plasmodium falcilparum Vietnamese isolate VI. Differentially expressed Leishmania genes and proteins have utility as vaccines, diagnostic reagents, as tools for the generation of immunological reagents and the generation of attenuated variants of Leishmania.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: October 17, 2000
    Assignee: McGill University
    Inventors: Gregory Matlashewski, Hugues Charest
  • Antibodies raised against proteins of Leishmania which are expressed at an increased level in the amastigote form
    Patent number: 5827671
    Abstract: Differentially expressed Leishmania genes and proteins are described. One differentially expressed gene (A2) is expressed at significantly elevated levels (more than about 10 fold higher) in the amastigote stage of the life cycle when the Leishmania organism is present in macrophages than in the free promastigote stage. The A2 gene encodes a 22 kD protein (A2 protein) that is recognized by kala-azar convalescent serum and has amino acid sequence homology with an S-antigen of Plasmodium falciparum Vietnamese isolate VI. Differentially expressed Leishmania genes and proteins have utility as vaccines, diagnostic reagents, as tools for the generation of immunological reagents and the generation of attenuated variants of Leishmania.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: October 27, 1998
    Assignee: McGill University
    Inventors: Gregory Matlashewski, Hugues Chareat
  • Protein of Leishmania which is expressed at an increased level in the amastigote form
    Patent number: 5780591
    Abstract: Differentially expressed Leishmania genes and proteins are described. One differentially expressed gene (A2) is expressed at significantly elevated levels (more than about 10 fold higher) in the amastigote stage of the life cycle when the Leishmania organism is present in macrophages than in the free promastigote stage. The A2 gene encodes a 22 kD protein (A2 protein) that is recognized by kala-azar convalescent serum and has amino acid sequence homology with an S-antigen of Plasmodium falciparum Vietnamese isolate VI. Differentially expressed Leishmania genes and proteins have utility as vaccines, diagnostic reagents, as tools for the generation of immunological reagents and the generation of attenuated variants of Leishmania.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 14, 1998
    Inventors: Gregory Matlashewski, Hugues Charest
  • A2 gene of leishmania which is differentially-expressed in amastigote form
    Patent number: 5733778
    Abstract: Differentially expressed Leishmania genes and proteins are described. One differentially expressed gene (A2) is expressed at significantly elevated levels (more than about 10 fold higher) in the amastigote stage of the life cycle when the Leishmania organism is present in macrophages than in the free promastigote stage. The A2 gene encodes a 22 kD protein (A2 protein) that is recognized by kala-azar convalescent serum and has amino acid sequence homology with an S-antigen of Plasmodium falciparum Vietnamese isolate VI. Differentially expressed Leishmania genes and proteins have utility as vaccines, diagnostic reagents, as tools for the generation of immunological reagents and the generation of attenuated variants of Leishmania.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: March 31, 1998
    Inventors: Gregory Matlashewski, Hugues Chareat